MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $280.00M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.55M
Average 0.73M
Returns on capital
MapLight Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.2%
avg -81.1%
ROIC
-36.4%
avg -73.5%
ROA
-33.6%
avg -56.9%
Analysis
ROA is currently the strongest return metric at -33.6% versus its period average of -56.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christopher A. Kroeger | Founder, President, Chief Executive Officer & Director | USD 1.01M | 58 | 1.20M | 2.81% |
Erin Pennock Foff | Chief Medical Officer | USD 745.85K | 49 | 296.91K | 0.70% |
Karl Deisseroth | Co-Founder & Member of Scientific Advisory Board | USD 147.36K | — | — | — |
Robert C. Malenka | Co-Founder & Member of Scientific Advisory Board | USD 147.36K | 71 | — | — |
Anatol Kreitzer | Chief Discovery Officer | — | 51 | 168.68K | 0.40% |
Karoly Nikolich | Founder & Member of Advisory Board | — | 78 | — | — |
Jonathan Gillis | Chief Admin & Acc Officer, PAO, Interim CFO & PFO | — | 45 | 142.31K | 0.33% |
James Woodruff Lillie | Chief Scientific Officer | — | 70 | 198.60K | 0.47% |
Kristopher L. Hanson | General Counsel & Secretary | — | 54 | — | — |
Compensation is shown in the reported currency; data updated Nov 14, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$65.54M
Sells
52
$12.71M
Net Transaction Value
+$52.82M
Net buying
Most Active
Foff Erin Pennock
10 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 15, 26Oct 15, 2026 | Foff Erin Pennock Direct | Sell | $124.1K$124,068.40 |
| Oct 15, 26Oct 15, 2026 | Kroeger Christopher A. Direct | Sell | $595.4K$595,423.28 |
| Oct 15, 26Oct 15, 2026 | GILLIS JONATHAN Direct | Sell | $82.1K$82,149.36 |
| Oct 15, 26Oct 15, 2026 | Lillie James Woodruff Direct | Sell | $93K$93,025.04 |
| Oct 15, 26Oct 15, 2026 | Kreitzer Anatol Direct | Sell | $96K$96,024.32 |
| Oct 15, 26Oct 15, 2026 | Hanson Kristopher Direct | Sell | $72.9K$72,881.60 |
| Sep 16, 26Sep 16, 2026 | Hanson Kristopher Direct | Sell | $192.7K$192,660.03 |
| Aug 14, 26Aug 14, 2026 | Catalyst4, Inc. Indirect | Buy | $50.1M$50,072,000.00 |
| Aug 14, 26Aug 14, 2026 | Catalyst4, Inc. Indirect | Buy | $292.9$292.87 |
| Aug 3, 26Aug 3, 2026 | Lillie James Woodruff Direct | Sell | $276.9K$276,908.28 |
1–10 of 59
Summary
Insiders reported 7 buys worth $65.54M and 52 sells worth $12.71M over the last 12 months. That adds up to net buying of $52.82M. Foff Erin Pennock was the most active insider with 10 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does MapLight Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about MPLT's management, answered from reported figures.
Who manages MPLT?
MapLight Therapeutics, Inc. (MPLT) lists 9 active executives. The top listed executive is Anatol Kreitzer, Chief Discovery Officer.
Are MPLT insiders buying or selling?
Recent insider activity shows net buying of $59.19M.
Continue the stock analysis
Jump to another research area for this company.